Differential regulation of the OASL and OAS1 genes in response to viral infections

Journal of Interferon and Cytokine Research

Volumn 29, Issue 4, 2009, Pages 199-207

  Melchjorsen, Jesper ^a,b   Kristiansen, Helle ^a   Christiansen, Rune ^a   Rintahaka, Johanna ^c   Matikainen, Sampsa ^c   Paludan, Søren R ^a   Hartmann, Rune ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Finnish Institute of Occupational Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DOUBLE STRANDED RNA; INTERFERON; INTERFERON REGULATORY FACTOR 3;

2' 5' OLIGOADENYLATE SYNTHETASE 1 GENE; 2' 5' OLIGOADENYLATE SYNTHETASE LIKE GENE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; MACROPHAGE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SENDAI VIRUS; UPREGULATION; VIRUS INFECTION;

2',5'-OLIGOADENYLATE SYNTHETASE; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; INFLUENZA A VIRUS; INTERFERON TYPE I; MACROPHAGES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENDAI VIRUS;

INFLUENZA A VIRUS; SENDAI VIRUS;

EID: 64549119779     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0050     Document Type: Article

References (43)

1. Chebath J, Benech P, Revel M, Vigneron M. 1987. Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection. Nature 330(6148):587-588.
2. Cohen B, Peretz D, Vaiman D, Benech P, Chebath J. 1988. Enhancerlike interferon responsive sequences of the human and murine (2'-5') oligoadenylate synthetase gene promoters. EMBO J 7(5):1411-1419.
3. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identifi cation of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 95(26):15623-15628.
4. Dong B, Silverman RH. 1995. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 270(8): 4133-4137.
5. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P and others. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4):896-906.
6. Elco CP, Guenther JM, Williams BR, Sen GC. 2005. Analysis of genes induced by Sendai virus infection of mutant cell lines reveals essential roles of interferon regulatory factor 3, NF-kappaB, and interferon but not toll-like receptor 3. J Virol 79(7):3920-3929.
7. Floyd-Smith G, Wang Q, Sen GC. 1999. Transcriptional induction of the p69 isoform of 2',5'-oligoadenylate synthetase by interferon- beta and interferon-gamma involves three regulatory elements and interferon-stimulated gene factor 3. Exp Cell Res 246(1):138-147.
8. Garcin D, Marq JB, Strahle L, le Mercier P, Kolakofsky D. 2002. All four Sendai Virus C proteins bind Stat1, but only the larger forms also induce its mono-ubiquitination and degradation. Virology 295(2):256-265.
9. Guille MJ, Laxton CD, Rutherford MN, Williams BR, Kerr IM. 1994.
10. Functional differences in the promoters of the interferon-inducible (2'-5')A oligoadenylate synthetase and 6-16 genes in interferon- resistant Daudi cells. Eur J Biochem 219(1-2):547-553.
11. Hartmann R, Olsen HS, Widder S, Jorgensen R, Justesen J. 1998. p59OASL, a 2'-5' oligoadenylate synthetase like protein: a novel human gene related to the 2'-5' oligoadenylate synthetase family. Nucleic Acids Res 26(18):4121-4128.
12. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA and others. 1998. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26(1):362-367.
13. Hilton L, Moganeradj K, Zhang G, Chen YH, Randall RE, McCauley JW, Goodbourn S. 2006. The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. J Virol 80(23):11723-11732.
14. Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6(9):644-658.
15. Hovanessian AG, Brown RE, Kerr IM. 1977. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 268(5620):537-540.
16. Justesen J, Hartmann R, Kjeldgaard NO. 2000. Gene structure and function of the 2'-5'-oligoadenylate synthetase family. Cell Mol Life Sci 57(11):1593-1612.
17. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ and others. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089):101-105.
18. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003.
19. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
20. Kotenko SV, Langer JA. 2004. Full house: 12 receptors for 27 cytokines. Int Immunopharmacol 4(5):593-608.
21. Lutfalla G, Holland SJ, Cinato E, Monneron D, Reboul J, Rogers NC, Smith JM, Stark GR, Gardiner K, Mogensen KE and others.
22. 1995. Mutant U5A cells are complemented by an interferonalpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 14(20):5100-5108.
23. Malathi K, Dong B, Gale M, Jr., Silverman RH. 2007. Small self-RNA generated by RNase L amplifi es antiviral innate immunity. Nature 448(7155):816-819.
24. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, Macdonald MR, Rice CM. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6):1887-1898.
25. Marques JT, Anwar J, Eskildsen-Larsen S, Rebouillat D, Paludan SR, Sen GC, Williams BR, Hartmann R. 2008. The p59 oligoadenylate synthetase like protein possesses antiviral activity which requires the C terminal ubiquitin-like domain. J Gen Virol 89(11):2767-72.
26. Nakaya T, Sato M, Hata N, Asagiri M, Suemori H, Noguchi S, Tanaka N, Taniguchi T. 2001. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 283(5):1150-1156.
27. Pellegrini S, John J, Shearer M, Kerr IM, Stark GR. 1989. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 9(11):4605-4612.
28. Peters KL, Smith HL, Stark GR, Sen GC. 2002. IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFNbeta genes in response to double-stranded RNA. Proc Natl Acad Sci USA 99(9):6322-6327.
29. Pfaffl MW. 2001. A new mathematical model for relative quantifi cation in real-time RT-PCR. Nucleic Acids Res 29(9):e45.
30. Quandt K, Frech K, Karas H, Wingender E, Werner T. 1995. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23(23):4878-4884.
31. Rebouillat D, Hovnanian A, David G, Hovanessian AG, Williams BR. 2000. Characterization of the gene encoding the 100-kDa form of human 2',5' oligoadenylate synthetase. Genomics 70(2):232-240.
32. Rebouillat D, Marie I, Hovanessian AG. 1998. Molecular cloning and characterization of two related and interferon-induced 56-kDa and 30-kDa proteins highly similar to 2'-5' oligoadenylate synthetase. Eur J Biochem 257(2):319-330.
33. Rintahaka J, Wiik D, Kovanen PE, Alenius H, Matikainen S. 2008. Cytosolic antiviral RNA recognition pathway activates caspases 1 and 3. J Immunol 180(3):1749-1757.
34. Roberts WK, Hovanessian A, Brown RE, Clemens MJ, Kerr IM. 1976. Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 264(5585):477-480.
35. Rubinstein M. 2007. The purifi cation and characterization of alpha interferons and related cytokine receptors-a personal account. Cytokine Growth Factor Rev 18(5-6):519-524.
36. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, Nakaya T, Katsuki M, Noguchi S, Tanaka N and others. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13(4):539-548.
37. Sen GC. 2001. Viruses and interferons. Annu Rev Microbiol 55:255-281.
38. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J and others. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R 1. Nat Immunol 4(1):63-68.
39. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
40. Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, Garcia-Sastre A. 2000. Activation of interferon regulatory factor 3 is inhibited by the infl uenza A virus NS1 protein. J Virol 74(17):7989-7996.
41. van Boxel-Dezaire AH, Rani MR, Stark GR. 2006. Complex modulation of cell type-specifi c signaling in response to type I interferons. Immunity 25(3):361-372.
42. Young HA, Bream JH. 2007. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol 316:97-117.
43. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81(14):7749-7758.